Communiqués PepGen Inc.

Actions

PEPG

US7133171055

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
16,57 ^USD	-4,44 %		+1,47 %	+143,68 %

15/05	La perte de PepGen au premier trimestre se réduit	MT
14/05	PepGen Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	14/05	GL
PepGen : Corporate Deck – May 2024	07/05	PU
PepGen to Participate in Upcoming Investor Conferences	13/03	GL
PepGen to Participate in Upcoming Investor Conferences	13/03	AQ
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	13/03	GL
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	13/03	AQ
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	06/03	GL
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	06/03	AQ
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03	GL
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03	AQ
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	20/02	GL
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock	07/02	GL
Mary Beth DeLena Joins PepGen as General Counsel and Secretary	17/01	GL
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping	08/01	GL
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)	18/12	GL
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors	15/11	GL
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	08/11	GL
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	08/11	AQ
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)	12/10/23	GL
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)	12/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués PepGen Inc.

Actions

PEPG

US7133171055

Communiqués

Filtres